HSPG2 and neoplasm: Perlecan domain V (LG1LG2LG3) promotes tissue repair and angiogenesis and can act as a proteoglycan in its own right, while the LG1LG2 and LG3 fragments of perlecan domain V inhibit endothelial, α2β1 integrin and VEGFA interactions required for blood vessel formation, and these fragments are of interest as anti-tumour therapeutic agents [74].